Humana faces severe headwinds from rising medical costs and a dramatic drop in 4-STAR Medicare Advantage membership, pressuring margins and profitability. Management is implementing STAR mitigation efforts and aggressive CenterWell and Medicaid expansion, targeting a turnaround by bonus year 2028. Despite near-term margin compression and operational risk, my DCF-based valuation of $330 per share suggests HUM is undervalued and presents a buying opportunity.
Investors need to pay close attention to Humana stock based on the movements in the options market lately.
HUM incurs a wider year-over-year loss in Q4 due to rising costs, weaker investment income and membership declines. Yet, revenues climb 12% on CenterWell strength.
| Health Care Providers & Services Industry | Healthcare Sector | James A. Rechtin CEO | XMUN Exchange | US4448591028 ISIN |
| US Country | 65,680 Employees | 27 Mar 2026 Last Dividend | 1 Aug 1991 Last Split | 22 Jan 1993 IPO Date |
Humana Inc., with its array of subsidiaries, stands as a major provider of medical and specialty insurance products across the United States. Initially established in 1961 and undergoing a name change from Extendicare Inc. to Humana Inc. in April 1974, the company is ingrained in the fabric of U.S. healthcare, having its roots and headquarters in Louisville, Kentucky. The organization operates through two primary segments: Insurance and CenterWell, showcasing a broad spectrum of health-related services and insurance products. Its purpose is deeply intertwined with offering extensive insurance coverage and healthcare services, primarily targeting individuals, employee groups, and military personnel.
Humana Inc.’s range of products and services underscores its commitment to providing comprehensive healthcare and insurance solutions. Here is a breakdown of its key offerings: